ワークショップ9 EGFR遺伝子変異陽性肺癌に対する治療戦略

[WS9-2] RELAY Phase 3 Trial in Untreated EGFR-Mutated Metastatic NSCLC：Final Overall Survival, Japan Subset

^○Takashi Seto¹, Makoto Nishio², Martin Reck³, Edward B. Garon⁴, Kazuto Nishio⁵, Kazuo Kasahara⁶, Kazumi Nishino⁷, Miyako Satouchi⁸, Kiyotaka Yoh⁹, Hidetoshi Hayashi¹⁰, Kazuko Sakai⁵, Sotaro Enatsu¹¹, Bente Frimodt-Moller¹², Tomoko Matsui¹¹, Sunoj Chacko Varughese¹³, Michelle Carlsen¹⁴, Carla M. Visseren-Grul¹⁵, Kazuhiko Nakagawa¹⁰ (1.Department of Thoracic Oncology, NHO Kyushu Cancer Center, Fukuoka, Japan, 2.Department of Thoracic Medical Oncology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan, 3.Department of Thoracic Oncology, Airway Research Center North, German Center for Lung Research, LungClinic, Grosshansdorf, Germany, 4.David Geffen School of Medicine at UCLA/TRIO-US Network, Los Angeles, USA, 5.Department of Genome Biology, Kindai University Faculty of Medicine, Osaka, Japan, 6.Department of Pulmonary Medicine and Oncology, Nippon Medical School Hospital, Tokyo, Japan, 7.Department of Thoracic Oncology, Osaka International Cancer Institute, Osaka, Japan, 8.Department of Thoracic Oncology, Hyogo Cancer Center, Hyogo, Japan, 9.Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Japan, 10.Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka, Japan, 11.Eli Lilly Japan K.K., Kobe, Japan, 12.Eli Lilly Denmark A/S, Copenhagen, Denmark, 13.Statistics, Eli Lilly Services India Pvt. Ltd., Bengaluru, India, 14.Eli Lilly and Company, Indianapolis, USA, 15.Eli Lilly Netherlands, Utrecht, The Netherlands)